Loading...

uniQure

Nasdaq:QURE
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
QURE
Nasdaq
$2B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • uniQure has significant price volatility in the past 3 months.
QURE Share Price and Events
7 Day Returns
-2.8%
NasdaqGS:QURE
-2.8%
US Biotechs
0.4%
US Market
1 Year Returns
77.8%
NasdaqGS:QURE
1.7%
US Biotechs
6.8%
US Market
QURE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
uniQure (QURE) -2.8% -14% 81.2% 77.8% 339% 488.3%
US Biotechs -2.8% -2.9% -0% 1.7% 5.7% 20.6%
US Market 0.4% 2.6% 11% 6.8% 38.1% 45.7%
1 Year Return vs Industry and Market
  • QURE outperformed the Biotechs industry which returned 1.7% over the past year.
  • QURE outperformed the Market in United States of America which returned 6.8% over the past year.
Price Volatility
QURE
Industry
5yr Volatility vs Market

Value

 Is uniQure undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of uniQure to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for uniQure.

NasdaqGS:QURE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:QURE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 25%) (1.68%))
1.315
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.32
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.315 * 5.96%)
10.57%

Discounted Cash Flow Calculation for NasdaqGS:QURE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for uniQure is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:QURE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.57%)
2019 -110.93 Analyst x4 -100.32
2020 -165.39 Analyst x4 -135.28
2021 -142.90 Analyst x3 -105.71
2022 -25.07 Analyst x3 -16.77
2023 174.49 Analyst x4 105.58
2024 285.43 Est @ 63.57% 156.19
2025 414.78 Est @ 45.32% 205.28
2026 549.77 Est @ 32.54% 246.08
2027 679.51 Est @ 23.6% 275.08
2028 797.33 Est @ 17.34% 291.91
Present value of next 10 years cash flows $922.04
NasdaqGS:QURE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $797.33 × (1 + 2.73%) ÷ (10.57% – 2.73%)
$10,447.29
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $10,447.29 ÷ (1 + 10.57%)10
$3,824.88
NasdaqGS:QURE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $922.04 + $3,824.88
$4,746.91
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,746.91 / 37.25
$127.45
NasdaqGS:QURE Discount to Share Price
Calculation Result
Value per share (USD) From above. $127.45
Current discount Discount to share price of $56.59
= -1 x ($56.59 - $127.45) / $127.45
55.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price uniQure is available for.
Intrinsic value
>50%
Share price is $56.59 vs Future cash flow value of $127.45
Current Discount Checks
For uniQure to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • uniQure's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • uniQure's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for uniQure's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are uniQure's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:QURE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.34
NasdaqGS:QURE Share Price ** NasdaqGS (2019-04-16) in USD $56.59
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 20.5x
United States of America Market PE Ratio Median Figure of 3,072 Publicly-Listed Companies 18.08x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of uniQure.

NasdaqGS:QURE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:QURE Share Price ÷ EPS (both in USD)

= 56.59 ÷ -2.34

-24.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • uniQure is loss making, we can't compare its value to the US Biotechs industry average.
  • uniQure is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does uniQure's expected growth come at a high price?
Raw Data
NasdaqGS:QURE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -24.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
40.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.73x
United States of America Market PEG Ratio Median Figure of 2,107 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for uniQure, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on uniQure's assets?
Raw Data
NasdaqGS:QURE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.81
NasdaqGS:QURE Share Price * NasdaqGS (2019-04-16) in USD $56.59
United States of America Biotechs Industry PB Ratio Median Figure of 412 Publicly-Listed Biotechs Companies 3.33x
United States of America Market PB Ratio Median Figure of 5,176 Publicly-Listed Companies 1.91x
NasdaqGS:QURE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:QURE Share Price ÷ Book Value per Share (both in USD)

= 56.59 ÷ 4.81

11.76x

* Primary Listing of uniQure.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • uniQure is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess uniQure's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. uniQure has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is uniQure expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is uniQure expected to grow at an attractive rate?
  • uniQure's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • uniQure's earnings growth is expected to exceed the United States of America market average.
  • uniQure's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:QURE Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:QURE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 40.8%
NasdaqGS:QURE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 64.2%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.5%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:QURE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:QURE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 422 282 262 6
2022-12-31 177 168 -6 6
2021-12-31 30 62 -117 5
2020-12-31 8 -115 -137 9
2019-12-31 7 -88 -114 8
NasdaqGS:QURE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 11 -76 -83
2018-09-30 12 -76 -89
2018-06-30 11 -71 -77
2018-03-31 13 -74 -78
2017-12-31 13 -64 -79
2017-09-30 20 -62 -67
2017-06-30 25 -65 -72
2017-03-31 24 -68 -71
2016-12-31 25 -72 -73
2016-09-30 20 -81 -76
2016-06-30 16 -62 -90
2016-03-31 14 5 -90

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • uniQure's earnings are expected to grow significantly at over 20% yearly.
  • uniQure's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:QURE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from uniQure Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:QURE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 5.43 6.25 4.21 4.00
2022-12-31 -0.16 2.09 -2.92 5.00
2021-12-31 -2.77 -1.99 -3.80 5.00
2020-12-31 -3.30 -2.29 -4.21 8.00
2019-12-31 -2.95 -2.62 -3.69 9.00
NasdaqGS:QURE Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.34
2018-09-30 -2.60
2018-06-30 -2.47
2018-03-31 -2.72
2017-12-31 -2.94
2017-09-30 -2.61
2017-06-30 -2.82
2017-03-31 -2.83
2016-12-31 -2.93
2016-09-30 -3.07
2016-06-30 -3.69
2016-03-31 -3.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if uniQure will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess uniQure's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
uniQure has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has uniQure performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare uniQure's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • uniQure does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare uniQure's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare uniQure's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
uniQure's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from uniQure Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:QURE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 11.28 -83.30 25.31
2018-09-30 12.26 -88.89 25.38
2018-06-30 11.37 -77.10 25.06
2018-03-31 13.26 -77.78 24.58
2017-12-31 13.11 -79.26 24.64
2017-09-30 19.65 -66.51 23.91
2017-06-30 24.62 -71.54 23.34
2017-03-31 24.12 -71.35 25.76
2016-12-31 25.10 -73.37 24.90
2016-09-30 19.94 -76.25 28.35
2016-06-30 16.30 -90.45 28.89
2016-03-31 13.61 -89.99 25.94
2015-12-31 10.58 -82.08 23.38
2015-09-30 8.20 -76.48 18.28
2015-06-30 5.79 -57.64 16.44
2015-03-31 4.97 -44.96 13.75
2014-12-31 6.14 -49.78 17.07
2014-09-30 5.18 -41.27 15.29
2014-06-30 6.02 -42.00 16.82
2014-03-31 5.67 -40.61 16.78
2013-12-31 4.05 -36.93 16.01
2013-09-30 2.78 -32.88 9.68 -6.99
2013-06-30 0.99 -27.10 7.73 -4.79
2013-03-31 -21.11 6.27 -2.36
2012-12-31 -19.40 6.02
2012-06-30 -1.64 -19.54 6.02 13.95

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if uniQure has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if uniQure has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if uniQure improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess uniQure's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
uniQure has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is uniQure's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up uniQure's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • uniQure is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • uniQure's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of uniQure's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from uniQure Company Filings, last reported 3 months ago.

NasdaqGS:QURE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 179.61 35.47 234.90
2018-09-30 199.85 20.71 239.55
2018-06-30 218.42 20.87 259.18
2018-03-31 100.26 20.81 140.82
2017-12-31 89.36 20.79 159.37
2017-09-30 19.61 20.59 88.93
2017-06-30 27.29 20.47 104.09
2017-03-31 45.73 20.36 120.27
2016-12-31 63.63 20.24 132.50
2016-09-30 81.36 20.56 157.74
2016-06-30 94.74 20.44 183.96
2016-03-31 115.33 20.47 210.29
2015-12-31 127.93 20.21 221.63
2015-09-30 145.59 20.43 239.38
2015-06-30 130.80 21.01 202.57
2015-03-31 36.28 22.59 46.41
2014-12-31 52.15 20.29 64.42
2014-09-30 64.62 20.69 79.24
2014-06-30 75.72 21.31 98.65
2014-03-31 85.47 11.46 106.83
2013-12-31 7.66 10.47 32.79
2013-09-30 15.32 11.91 42.54
2013-06-30 -16.12 31.56 12.48
2013-03-31 -0.57 2.69 0.34
2012-12-31 -0.59 2.77 0.35
2012-06-30
  • uniQure's level of debt (19.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (122.9% vs 19.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • uniQure has sufficient cash runway for 2.9 years based on current free cash flow.
  • uniQure has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 25.9% each year.
X
Financial health checks
We assess uniQure's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. uniQure has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is uniQure's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from uniQure dividends.
If you bought $2,000 of uniQure shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate uniQure's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate uniQure's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:QURE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:QURE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as uniQure has not reported any payouts.
  • Unable to verify if uniQure's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of uniQure's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as uniQure has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess uniQure's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can uniQure afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. uniQure has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of uniQure's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Matt Kapusta
COMPENSATION $3,929,534
AGE 46
TENURE AS CEO 2.3 years
CEO Bio

Mr. Matthew Craig Kapusta, also known as Matt, has been the Chief Executive Officer of uniQure N.V. since December 19, 2016 and serves as its Interim Chief Financial Officer. Mr. Kapusta served as a Chief Financial Officer of uniQure N.V. since January 01, 2015. Mr. Kapusta served as an Interim Chief Executive Officer of uniQure N.V. from September 22, 2016 to December 19, 2016. He served as Member of Management Board at uniQure N.V. since June 10, 2015 until June 15, 2016. Mr. Kapusta served as the Senior Vice President of Business Development at AngioDynamics Inc., since November 15, 2011. He served as Vice President at C.E. Unterberg, Towbin. He was employed at FleetBoston Robertson Stephens, Inc. Mr. Kapusta has nearly 20 years of life science industry experience from investment banking and finance, as well as corporate development positions. He served as Vice President of Healthcare Mergers and Acquisitions at Wells Fargo Securities. Mr. Kapusta helped establish the New York Wells Fargo Securities office and helped create its investment banking training program. He has held several positions in the investment banking and equity space, including his role as Managing Director, Healthcare Investment Banking at Collins Stewart and leadership positions at Wells Fargo Securities and Robertson Stephens. He has advised on more than 50 transactions valued at over $6 billion. He served as Vice President of Strategic Planning and Financial Analysis for Smith & Nephew Orthopaedics, he formed the Business Intelligence and Analytics team responsible for developing data-driven insights and understanding of business performance, such as surgeon attrition, sales force productivity and asset efficiency. He served as Vice President of Finance for Smith & Nephew Orthopaedics. Mr. Kapusta also spearheaded strategic and financial planning for Smith & Nephew's global Hips, Knees and Trauma franchises, identifying significant cost efficiencies that were reinvested to fund key strategic initiatives. Mr. Kapusta was a Senior Associate at Robertson Stephens, Inc., and an associate at Painewebber, Inc. Mr. Kapusta was one of two bankers to receive Wells Fargo's 2005 Golden Spoke Award for exceptional performance and contribution. He has been a Director at uniQure N.V. since June 15, 2016. He holds a BBA in finance and Accounting from the University of Michigan and an MBA in finance and business management from New York University. He earned his Certified Public Accountant license in 1996.

CEO Compensation
  • Matt's compensation has increased whilst company is loss making.
  • Matt's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the uniQure management team in years:

2.3
Average Tenure
51.5
Average Age
  • The tenure for the uniQure management team is about average.
Management Team

Matt Kapusta

TITLE
CEO, CFO & Executive Director
COMPENSATION
$4M
AGE
46
TENURE
2.3 yrs

Sander van Deventer

TITLE
Co-founder
COMPENSATION
$129K
AGE
64

Jon Garen

TITLE
Chief Business Officer
COMPENSATION
$1M
AGE
52
TENURE
2.8 yrs

Hugo Katus

TITLE
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany

Scott McMillan

TITLE
Chief Operating Officer
AGE
59
TENURE
1.7 yrs

Christian Klemt

TITLE
Chief Accounting Officer
AGE
45
TENURE
1.7 yrs

Maria Cantor

TITLE
Senior Vice President of Investor Relations & Communication
AGE
50
TENURE
2.8 yrs

David Cerveny

TITLE
Chief Legal Officer
AGE
51
TENURE
1.1 yrs

Tamara Tugal

TITLE
Business Development Director
TENURE
10.8 yrs

Alex Kuta

TITLE
Senior Vice President of Regulatory Affairs
AGE
58
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the uniQure board of directors in years:

2.6
Average Tenure
61
Average Age
  • The average tenure for the uniQure board of directors is less than 3 years, this suggests a new board.
Board of Directors

Philip Astley-Sparke

TITLE
Chairman
COMPENSATION
$275K
AGE
47
TENURE
2.6 yrs

Matt Kapusta

TITLE
CEO, CFO & Executive Director
COMPENSATION
$4M
AGE
46
TENURE
2.8 yrs

Hugo Katus

TITLE
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
TENURE
4.7 yrs

Robert Gut

TITLE
Chief Medical Officer & Executive Director
AGE
53
TENURE
0.8 yrs

Jack Kaye

TITLE
Non-Executive Director
COMPENSATION
$147K
AGE
74
TENURE
2.8 yrs

Madhu Balachandran

TITLE
Non-Executive Director
COMPENSATION
$15K
AGE
67
TENURE
1.6 yrs

Jeremy Springhorn

TITLE
Non-Executive Director
COMPENSATION
$19K
AGE
56
TENURE
1.6 yrs

Jesús Prieto

TITLE
Member of Scientific Advisory Board

Kathy High

TITLE
Member of Scientific Advisory Board
AGE
66

Michael Hayden

TITLE
Member of Scientific Advisory Board
AGE
67
Who owns this company?
Recent Insider Trading
  • uniQure insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
03. Apr 19 Sell Coller Capital Ltd. Company 26. Mar 19 02. Apr 19 -257,603 $62.18 $-15,503,718
31. Jan 19 Sell Jack Kaye Individual 28. Jan 19 28. Jan 19 -1,210 $31.31 $-37,885
30. Jan 19 Sell Madhavan Balachandran Individual 28. Jan 19 28. Jan 19 -1,210 $31.31 $-37,885
30. Jan 19 Sell Jeremy Springhorn Individual 28. Jan 19 28. Jan 19 -1,210 $31.32 $-37,897
30. Jan 19 Sell Paula Soteropoulos Individual 28. Jan 19 28. Jan 19 -1,210 $31.32 $-37,897
30. Jan 19 Sell David Schaffer Individual 28. Jan 19 28. Jan 19 -1,210 $31.31 $-37,885
30. Jan 19 Sell Philip Astley-Sparke Individual 28. Jan 19 28. Jan 19 -1,210 $31.32 $-37,897
30. Jan 19 Sell Sander van Deventer Individual 28. Jan 19 28. Jan 19 -1,358 $31.31 $-42,519
30. Jan 19 Sell Christian Klemt Individual 28. Jan 19 28. Jan 19 -1,479 $31.29 $-46,278
30. Jan 19 Sell Scott McMillan Individual 28. Jan 19 28. Jan 19 -591 $31.23 $-18,457
30. Jan 19 Sell Alexander Kuta Individual 28. Jan 19 28. Jan 19 -1,052 $31.29 $-32,917
07. Jan 19 Sell Christian Klemt Individual 03. Jan 19 03. Jan 19 -5,739 $27.91 $-160,175
08. Jun 18 Sell Steven Zelenkofske Individual 06. Jun 18 06. Jun 18 -23,929 $37.14 $-888,723
X
Management checks
We assess uniQure's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. uniQure has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Read This Before Buying uniQure N.V. (NASDAQ:QURE) Shares

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So we'll take a look at whether insiders have been buying or selling shares in uniQure N.V. … But logic dictates you should pay some attention to whether insiders are buying or selling shares.

Simply Wall St -

What Kind Of Shareholders Own uniQure N.V. (NASDAQ:QURE)?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … We also tend to see lower insider ownership in companies that were previously publicly owned. … It has a market capitalization of US$2.5b, which means it would generally expect to see some institutions on the share registry.

Simply Wall St -

uniQure Shareholders Have Enjoyed An Impressive 175% Share Price Gain

Given that uniQure didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. … Over the last three years uniQure has grown its revenue at 2.2% annually.

Simply Wall St -

Is uniQure N.V. (NASDAQ:QURE) A Volatile Stock?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Do Institutions Own Shares In uniQure NV (NASDAQ:QURE)?

The big shareholder groups in uniQure NV (NASDAQ:QURE) have power over the company. … Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … With a market capitalization of US$1.2b, uniQure is a decent size, so it is probably on the radar of institutional investors.

Simply Wall St -

uniQure NV (NASDAQ:QURE): What Can We Expect In The Future?

In March 2018, uniQure NV (NASDAQ:QURE) released its earnings update. … as a -15.00% fall in profits is expected in the upcoming year … this is still an improvement on its past 5-year earnings growth rate of -21.82%, on average.

Simply Wall St -

uniQure NV (NASDAQ:QURE) Is Expected To Breakeven

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. … With the latest financial year loss of -US$79.26m and a trailing-twelve month of -US$77.78m, the US$1.32b market-cap alleviates its loss by moving closer towards its target of breakeven? … See our latest analysis for uniQure

Simply Wall St -

uniQure NV. (NASDAQ:QURE): Risks You Need To Consider Before Buying

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … QURE’s beta indicates it is a stock that investors may find valuable if they want to reduce the overall market risk exposure of their stock portfolio. … Thus, we can expect QURE to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.

Simply Wall St -

Did uniQure NV's (NASDAQ:QURE) Earnings Growth Outperform The Industry?

View our latest analysis for uniQure How Did QURE's Recent Performance Stack Up Against Its Past? … For the purpose of this commentary, I like to use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … This shows that, uniQure has historically performed better than recently, despite the fact that it seems like earnings are now heading back towards to right direction again.

Simply Wall St -

Company Info

Description

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington’s disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Details
Name: uniQure N.V.
QURE
Exchange: NasdaqGS
Founded: 1998
$2,107,724,486
37,245,529
Website: http://www.uniqure.com
Address: uniQure N.V.
Paasheuvelweg 25a,
Amsterdam,
Noord-Holland, 1105 BP,
Netherlands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS QURE Ordinary Shares Nasdaq Global Select US USD 05. Feb 2014
LSE 0EE0 Ordinary Shares London Stock Exchange GB USD 05. Feb 2014
Number of employees
Current staff
Staff numbers
212
uniQure employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 00:51
End of day share price update: 2019/04/16 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.